Novavax and Israel's Ministry of Health announced an agreement for the purchase of NVX-CoV2373, the company's recombinant nanoparticle protein-based Covid-19 vaccine candidate with Matrix-M adjuvant.

"Israel has been at the forefront of the fight against Covid-19 and has demonstrated strong leadership throughout the pandemic," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We thank the Israeli Ministry of Health for their commitment to providing a protein-based Covid-19 vaccine option, based on well-understood technology, to the people of Israel."   

Under the advance purchase agreement, Novavax will provide an initial 5 million doses of its protein-based vaccine with an option for Israel to purchase an additional 5 million doses. Novavax will work with the Ministry of Health to obtain the necessary authorizations and finalize plans for distribution in Israel pending regulatory approval.

Novavax received conditional marketing authorization for NVX-CoV2373 in the European Union and emergency use listing (EUL) from the World Health Organisation (WHO), among others. The vaccine is also currently under review by multiple regulatory agencies worldwide. The company submitted its complete chemistry, manufacturing and controls (CMC) data package to the U.S. Food and Drug Administration (FDA) at the end of 2021 and expects to submit a request for EUA for the vaccine in the U.S. after one month in accordance with guidance from the FDA regarding submission of all EUA vaccines.